Mesothelin immunotherapy for cancer: Ready for prime time?

Journal of Clinical Oncology

Volumn 34, Issue 34, 2016, Pages 4171-4179

  Hassan, Raffit ^a   Thomas, Anish ^a   Alewine, Christine ^a   Le, Dung T ^b   Jaffee, Elizabeth M ^b   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMATUXIMAB; ANETUMAB RAVTANSINE; ANTIBODY DRUG CONJUGATE; BMS 986148; CANCER VACCINE; CHIMERIC ANTIGEN RECEPTOR; CRS 207; DMOT 4039A; IMMUNOTOXIN; IMMUNOTOXIN SS1P; JNJ 64041757; LMB 100; MESOTHELIN; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MAYTANSINE; MONOCLONAL ANTIBODY; MORAB-009 MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; MESOTHELIOMA; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; T LYMPHOCYTE; ANALOGS AND DERIVATIVES; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GPI-LINKED PROTEINS; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; MAYTANSINE; NEOPLASMS;

EID: 84997235832     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.68.3672     Document Type: Article

References (87)

1. Chang K, Pastan I, Willingham MC: Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 50:373-381, 1992
2. Chang K, Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 93:136-140, 1996
3. Ordóñez NG: Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 27:1418-1428, 2003
4. Chang K, Pai LH, Pass H, et al: Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 16: 259-268, 1992
5. Hassan R, Kreitman RJ, Pastan I, et al: Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 13:243-247, 2005
6. Argani P, Iacobuzio-Donahue C, Ryu B, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: Identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7:3862-3868, 2001
7. Hassan R, Laszik ZG, Lerner M, et al: Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 124:838-845, 2005
8. Thomas A, Chen Y, Steinberg SM, et al: High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget 6:11694-11703, 2015
9. Kachala SS, Bograd AJ, Villena-Vargas J, et al: Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrencefree and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 20:1020-1028, 2014 [Erratum20: 3896, 2014]
10. Tozbikian G, Brogi E, Kadota K, et al: Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. PLoS One 9: e114900, 2014
11. Steinbach D, Onda M, Voigt A, et al: Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. Eur J Haematol 79:281-286, 2007
12. Hassan R, Wu C, Brechbiel MW, et al: 111Indium-labeled monoclonal antibody K1: Biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int J Cancer 80:559-563, 1999
13. Lindenberg L, Thomas A, Adler S, et al: Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. Oncotarget 6: 4496-4504, 2015
14. Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, et al: ImmunoPET with antimesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatment. Clin Cancer Res 22:1642-1652, 2016
15. Pastan I, Hassan R: Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Res 74:2907-2912, 2014
16. Hassan R, Bullock S, Premkumar A, et al: Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144-5149, 2007
17. Yamaguchi N, Hattori K, Oh-eda M, et al: A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 269:805-808, 1994
18. Zhang Y, Chertov O, Zhang J, et al: Cytotoxic activity of immunotoxin SS1P is modulated by TACEdependent mesothelin shedding. Cancer Res 71: 5915-5922, 2011
19. Zwaenepoel I, Mustapha M, Leibovici M, et al: Otoancorin, an inner ear protein restricted to the interface between the apical surface of sensory epithelia and their overlying acellular gels, is defective in autosomal recessive deafness DFNB22. Proc Natl Acad Sci USA 99:6240-6245, 2002
20. Sathyanarayana BK, Hahn Y, Patankar MS, et al: Mesothelin, stereocilin, and otoancorin are predicted to have superhelical structures with ARMtype repeats. BMC Struct Biol 9:1, 2009
21. Ma J, Tang WK, Esser L, et al: Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009. Acta Crystallogr Sect F Struct Biol Cryst Commun 68: 950-953, 2012
22. Bera TK, Pastan I: Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 20:2902-2906, 2000
23. GallowayML, Murray D, Moffat DF: The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies. Histopathology 48:767-769, 2006
24. Kushitani K, Takeshima Y, Amatya VJ, et al: Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. Pathol Int 57:190-199, 2007
25. Miettinen M, Sarlomo-Rikala M: Expression of calretinin, thrombomodulin, keratin 5, andmesothelin in lung carcinomas of different types: An immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura. Am J Surg Pathol 27:150-158, 2003
26. Ordó ñez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 16:192-197, 2003
27. Tan K, Kajino K, Momose S, et al: Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter. Hum Pathol 41:1330-1338, 2010
28. Illei PB, Alewine C, Zahurak M, et al: Mesothelin expression in advanced gastroesophageal cancer represents a novel target for immunotherapy. Appl Immunohistochem Mol Morphol 24:246-252, 2016
29. Scales SJ, Gupta N, Pacheco G, et al: An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol Cancer Ther 13: 2630-2640, 2014
30. Frierson HF Jr, Moskaluk CA, Powell SM, et al: Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 34:605-609, 2003
31. Swierczynski SL, Maitra A, Abraham SC, et al: Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum Pathol 35:357-366, 2004
32. Winter JM, Tang LH, Klimstra DS, et al: A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One 7:e40157, 2012 [Erratum: PLoS One 7, 2012]
33. Shimizu A, Hirono S, Tani M, et al: Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci 103:739-746, 2012
34. Yen MJ, Hsu CY, Mao TL, et al: Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 12:827-831, 2006
35. Cheng WF, Huang CY, Chang MC, et al: High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer 100:1144-1153, 2009
36. Ho M, Bera TK, Willingham MC, et al: Mesothelin expression in human lung cancer. Clin Cancer Res 13:1571-1575, 2007
37. Alvarez H, Rojas PL, Yong KT, et al:Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: Translational implications for diagnosis and therapy. Nanomedicine (Lond) 4:295-301, 2008
38. Baba K, Ishigami S, Arigami T, et al: Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 105:195-199, 2012
39. Einama T, Homma S, Kamachi H, et al: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer 107:137-142, 2012
40. Ito T, Kajino K, Abe M, et al: ERC/mesothelin is expressed in human gastric cancer tissues and cell lines. Oncol Rep 31:27-33, 2014
41. Kawamata F, Kamachi H, Einama T, et al: Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer. Int J Oncol 41:2109-2118, 2012
42. Nomura R, Fujii H, Abe M, et al: Mesothelin expression is a prognostic factor in cholangiocellular carcinoma. Int Surg 98:164-169, 2013
43. Zhao H, Davydova L, Mandich D, et al: S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct. Am J Clin Pathol 127:374-379, 2007
44. Obulhasim G, Fujii H, Matsumoto T, et al: Mesothelin gene expression and promoter methylation/hypomethylation in gynecological tumors. Eur J Gynaecol Oncol 31:63-71, 2010
45. Li YR, Xian RR, Ziober A, et al: Mesothelin expression is associated with poor outcomes in breast cancer. Breast Cancer Res Treat 147:675-684, 2014
46. Tchou J, Wang LC, Selven B, et al: Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 133: 799-804, 2012
47. Rump A, Morikawa Y, Tanaka M, et al: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 279: 9190-9198, 2004
48. Gubbels JA, Belisle J, Onda M, et al: Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 5:50, 2006
49. Uehara N, Matsuoka Y, Tsubura A:Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res 6:186-193, 2008
50. Servais EL, Colovos C, Rodriguez L, et al: Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 18:2478-2489, 2012
51. Chen SH, Hung WC, Wang P, et al: Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep 3:1870, 2013
52. Chang MC, Chen CA, Chen PJ, et al: Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem J 442:293-302, 2012
53. Bharadwaj U, Marin-Muller C, Li M, et al: Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis 32:1013-1024, 2011
54. Bharadwaj U, Marin-Muller C, Li M, et al: Mesothelin confers pancreatic cancer cell resistance to TNF-a-induced apoptosis through Akt/PI3K/NF-kB activation and IL-6/Mcl-1 overexpression. Mol Cancer 10:106, 2011
55. Sato N, Maitra A, Fukushima N, et al: Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Res 63: 4158-4166, 2003
56. Hucl T, Brody JR, Gallmeier E, et al: High cancer-specific expression of mesothelin (MSLN) is attributable to an upstream enhancer containing a transcription enhancer factor dependent MCAT motif. Cancer Res 67:9055-9065, 2007
57. Ren YR, Patel K, Paun BC, et al: Structural analysis of the cancer-specific promoter in mesothelin and in other genes overexpressed in cancers. J Biol Chem 286:11960-11969, 2011
58. Marin-Muller C, Li D, Bharadwaj U, et al: A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer. Clin Cancer Res 19:5901-5913, 2013
59. Chowdhury PS, Viner JL, Beers R, et al: Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci USA 95:669-674, 1998
60. Chowdhury PS, Pastan I: Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 17:568-572, 1999
61. Pastan I, Hassan R, Fitzgerald DJ, et al: Immunotoxin therapy of cancer. Nat Rev Cancer 6: 559-565, 2006
62. Kreitman RJ, Hassan R, Fitzgerald DJ, et al: Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15: 5274-5279, 2009
63. Hassan R, Sharon E, Thomas A, et al: Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for frontline therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer 120:3311-3319, 2014
64. Hassan R, Miller AC, Sharon E, et al: Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med 5:208ra147, 2013
65. Hassan R, Alewine C, Pastan I: New life for immunotoxin cancer therapy. Clin Cancer Res 22: 1055-1058, 2016
66. Hollevoet K, Mason-Osann E, Liu XF, et al: In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer. Mol Cancer Ther 13:2040-2049, 2014
67. Alewine C, Xiang L, Yamori T, et al: Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers. Mol Cancer Ther 13:2653-2661, 2014
68. Liu W, Onda M, Lee B, et al: Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc Natl Acad Sci USA 109: 11782-11787, 2012
69. Jaffee EM, Hruban RH, Biedrzycki B, et al: Novel allogeneic granulocyte-macrophage colonystimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol 19:145-156, 2001
70. Thomas AM, Santarsiero LM, Lutz ER, et al: Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J ExpMed 200:297-306, 2004
71. Brockstedt DG, Giedlin MA, Leong ML, et al: Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci USA 101:13832-13837, 2004
72. Le DT, Brockstedt DG, Nir-Paz R, et al: A liveattenuated Listeria vaccine (ANZ-100) and a liveattenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin Cancer Res 18: 858-868, 2012
73. Hassan R, Ebel W, Routhier EL, et al: Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun 7:20, 2007
74. Hassan R, Cohen SJ, Phillips M, et al: Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelinexpressing cancers. Clin Cancer Res 16:6132-6138, 2010
75. Golfier S, Kopitz C, Kahnert A, et al: Anetumab ravtansine: A novel mesothelin-targeting antibodydrug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 13:1537-1548, 2014
76. Hassan R, Blumenschein G Jr, Kindler HL, et al: Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine. Presented at the 16th World Conference on Lung Cancer, Denver, CO, September 6-9, 2015
77. Weekes CD, Lamberts LE, Borad MJ, et al: Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther 15:439-447, 2016
78. Morello A, Sadelain M, Adusumilli PS: Mesothelin-targeted CARs: Driving T cells to solid tumors. Cancer Discov 6:133-146, 2016
79. O'Hara M, Stashwick C, Haas AR, et al: Mesothelin as a target for chimeric antigen receptormodified T cells as anticancer therapy. Immunotherapy 8:449-460, 2016
80. Beatty GL, Haas AR, Maus MV, et al: Mesothelin-specific chimeric antigen receptor mRNAengineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2:112-120, 2014
81. Adusumilli PS, Cherkassky L, Villena-Vargas J, et al: Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 6:261ra151, 2014
82. Hassan R, Williams-Gould J, Watson T, et al: Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 10:16-18, 2004
83. Mossoba ME, Onda M, Taylor J, et al: Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts. Clin Cancer Res 17:3697-3705, 2011
84. Hassan R, Kindler HL, Jahan T, et al: Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res 20:5927-5936, 2014
85. Gupta A, Hussein Z, Hassan R, et al: Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection. Cancer Chemother Pharmacol 77:733-743, 2016
86. Hassan R, Antonia S, Alley E, et al: Antimesothelin vaccine CRS-207 plus chemotherapy as front-line treatment for malignant pleural mesothelioma (MPM). Presented at the European Cancer Congress, Vienna, Austria, September 25-29, 2015
87. Le DT, Wang-Gillam A, Picozzi V, et al: Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 33:1325-1333, 2015